ProShare Advisors
VBIV

ProShare Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

ProShare Advisors’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-756
Closed -$6.88K – 1928
2023
Q1 		$6.88K Sell
756
-71
-9% -$1.01K ﹤0.01% 1775
2022
Q4 		$9.7K Buy
827
+119
+17% +$2.1K ﹤0.01% 1832
2022
Q3 		$15K Sell
708
-14
-2% -$377 ﹤0.01% 1728
2022
Q2 		$17K Sell
722
-456
-39% -$15.5K ﹤0.01% 1776
2022
Q1 		$59K Sell
1,178
-194
-14% -$9.59K ﹤0.01% 2103
2021
Q4 		$97K Buy
1,372
+577
+73% +$48.6K ﹤0.01% 2210
2021
Q3 		$74K Sell
795
-815
-51% -$77.4K ﹤0.01% 1946
2021
Q2 		$162K Buy
1,610
+5
+0.3% +$487 ﹤0.01% 2201
2021
Q1 		$150K Buy
1,605
+274
+21% +$27.8K ﹤0.01% 2107
2020
Q4 		$110K Buy
1,331
+629
+90% +$53.6K ﹤0.01% 1977
2020
Q3 		$60K Sell
702
-76
-10% -$8.86K ﹤0.01% 1578
2020
Q2 		$72K Buy
+778
New +$42.9K ﹤0.01% 1607
2020
Q1 		– Sell
-692
Closed -$29K – 1650
2019
Q4 		$29K Buy
+692
New +$15.2K ﹤0.01% 1769

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ProShare Advisors's VBIV Position: Q2 2023 in Review

ProShare Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 756 shares — an estimated $6.88K sold.

ProShare Advisors first reported a position in VBIV in Q4 2019 and held it in 13 quarters. The position peaked at $162K in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • ProShare Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • ProShare Advisors sold 756 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $6.88K.
  • ProShare Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 13 quarters.
  • ProShare Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $162K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.